Patient-Reported Outcome Measures in Oncology Drugs Approved by the European Medicines Agency, 2017-2021

被引：8

作者：

Ciani, Oriana ^{[1
]}

Meregaglia, Michela ^{[1
]}

De Lorenzo, Francesco ^{[2
]}

Perrone, Francesco ^{[3
,4
]}

Pinto, Carmine ^{[5
,6
]}

机构：

[1] SDA Bocconi, Ctr Res Hlth & Social Care Management, Milan, Italy

[2] Italian Federat Oncol Voluntary Associat, Rome, Italy

[3] Natl Canc Inst, Clin Trials Unit, Naples, Italy

[4] Italian Assoc Med Oncol, Milan, Italy

[5] Ist Ricovero & Cura Carattere Sci Azienda Unita, Comprehens Canc Ctr, Reggio Emilia, Italy

[6] Federat Italian Cooperat Oncol Groups, Florence, Italy

来源：

JAMA NETWORK OPEN | 2023年 / 6卷 / 01期

关键词：

D O I：

10.1001/jamanetworkopen.2022.51564

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页数：3

共 6 条

[1]

Basch E, 2018, LANCET ONCOL, V19, P595, DOI 10.1016/S1470-2045(18)30141-4

[2]

EQUATOR Network, The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies

[3]

European Medicines Agency, EMA regulatory science to 2025: strategic reflection

[4]

European Medicines Agency, European public assessment reports: background and context

[5]

European Medicines Agency, Patient experience data in EU medicines development and regulatory decision-making

[6]

Kluetz PG, 2018, LANCET ONCOL, V19, pE267, DOI 10.1016/S1470-2045(18)30097-4

← 1 →